CoChat

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

GLP-1 receptor agonists: a review of head-to-head clinical studies

Open access
Trujillo, Jennifer M., Nuffer, Wesley, Ellis, Samuel L. · 2015 · Therapeutic Advances in Endocrinology and Metabolism

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while having a low risk of hypoglycemia. The GLP-1 RA class has grown in the last decade with several agents available for use in the US and Europe and several more in development. Since the efficacy and tolerability, dosing frequency, administration requirements, and cost may vary between agents within the class, each agent may offer unique advantages and disadvantages. Through a review of phase III clinical programs for exenatide twice daily, exenatide once weekly, liraglutide, albiglutide, lixisenatide, and dulaglutide, eight head-to-head trials have evaluated the safety and efficacy of GLP-1 RA active comparators. The purpose of this review is to provide an analysis of these trials. The GLP-1 RA head-to-head clinical studies have demonstrated that all GLP-1 RA agents are effective therapeutic options at reducing A1C. However, differences exist in terms of magnitude of effect on A1C and weight as well as frequency and severity of adverse effects.

Overview

Integrity signals

Registry

Crossref · 10.1177/2042018814559725

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 17 references

Cited by

See all 284

Metadata

Authors
Trujillo, J. M., Nuffer, W., & Ellis, S. L.
Affiliations
  • University of Colorado System (US)
  • University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA
Venue
Therapeutic Advances in Endocrinology and Metabolism
Published
2014-11-25
Volume
6
Issue
1
Pages
19-28
ISSN
  • 2042-0188 (ISSN-L)
  • 2042-0196
OpenAlex
W2097771449
Cited by
282
References
17
Citations by year
2026: 6 · 2025: 11 · 2024: 11 · 2023: 22 · 2022: 15 · 2021: 23 · 2020: 19 · 2019: 45 · 2018: 41 · 2017: 38 · 2016: 37 · 2015: 13
FWCI
23.61
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Therapeutic Advances in Endocrinology and Metabolism (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
GLP-1 receptor agonists, type 2 diabetes, exenatide twice daily, liraglutide, albiglutide, lixisenatide, dulaglutide, weight loss, adverse effects, drug efficacy and tolerability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 receptor agonists: a review of head-to-head clinical studies. https://app.cochat.ai/papers/10.1177/2042018814559725
The paper
Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2015). GLP-1 receptor agonists: a review of head-to-head clinical studies. Therapeutic Advances in Endocrinology and Metabolism. https://doi.org/10.1177/2042018814559725

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.